STANDARD BIOTLS (LAB)
(Delayed Data from NSDQ)
$2.10 USD
+0.11 (5.53%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $2.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Standard BioTools (LAB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.08 | $4.00 | $2.50 | 54.77% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Standard BioTools comes to $3.08. The forecasts range from a low of $2.50 to a high of $4.00. The average price target represents an increase of 54.77% from the last closing price of $1.99.
Analyst Price Targets (3 )
Broker Rating
Standard BioTools currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/31/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
9/5/2024 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $3.08 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 74 of 252 |
Current Quarter EPS Est: | -0.07 |
LAB FAQs
Standard BioTools Inc. (LAB) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Standard BioTools Inc. (LAB) is $3.08. The current on short-term price targets is based on 1 reports.
The forecasts for Standard BioTools Inc. (LAB) range from a low of $2.5 to a high of $4. The average price target represents a increase of $54.77 from the last closing price of $1.99.
The current UPSIDE for Standard BioTools Inc. (LAB) is 54.77%
Based on short-term price targets offered by three analysts, the average price target for Standard BioTools comes to $3.08. The forecasts range from a low of $2.50 to a high of $4.00. The average price target represents an increase of 54.77% from the last closing price of $1.99.